A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Xu, Dao Zhen ^a   Zhao, Kai ^b   Guo, Li Min ^a   Chen, Xin Yue ^c   Wang, Hui Fen ^d   Zhang, Ji Ming ^e   Xie, Qin ^f   Ren, Hong ^g   Wang, Wen Xiang ^g   Li, Lan Juan ^h   Xu, Min ⁱ   Liu, Pei ^j   Niu, Jun Qi ^k   Bai, Xue Fan ^l   Shen, Xin Liang ^b   Yuan, Zheng Hong ^m   Wang, Xuan Yi ^m   Wen, Yu Mei ^m  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Biological Products   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d 302 MILITARY HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g CHONGQING MEDICAL UNIVERSITY   (China)

^h ZHEJIANG UNIVERSITY   (China)

ⁱ Guangzhou Eighth Hospital   (China)

^j CHINA MEDICAL UNIVERSITY   (China)

^k JILIN UNIVERSITY   (China)

^l FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^m FUDAN UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIVIRUS AGENT; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; PLACEBO; VIRUS DNA; YEAST DERIVED HEPATITIS B SURFACE ANTIGEN AND HEPATITIS B SURFACE ANTIBODY VACCINE; YIC VACCINE;

ACTIVE IMMUNIZATION; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; GENE REPRESSION; HEPATITIS B; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REBOUND; SEROCONVERSION; SIDE EFFECT; VIRUS REPLICATION; ADOLESCENT; IMMUNOLOGY; KINETICS; METABOLISM; MIDDLE AGED;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; DNA, VIRAL; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; KINETICS; MIDDLE AGED;

EID: 50149120755     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002565     Document Type: Article

References (30)

1. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
2. Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
3. Bertoletti A, Ferrari C (2003) Kinetics of the immune response during HBV and HCV infection. Hepatology 38: 4-13.
4. Chisari FV, Ferrari C (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29-60.
5. Ganem D, Prince AM (2004) Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129.
6. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, et al. (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78: 5707-5719.
7. Sprengers D, Janssen HL (2005) Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 19: 17-26.
8. Pol S, Driss F, Michel ML. Nalpas B, Berthelot P, et al. (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342.
9. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, et al. (1996) DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 93: 12496-12501.
10. Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, et al. (2001) DNA prime/ canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33: 448-454.
11. Akbar SMF, Furukawa S, Onji M, Murata Y, Niya T, et al. (2004) Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 29: 136-141.
12. Mancini-Bourgine M, Fontaine H, Brechot C, S SP, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24: 4482-4189.
13. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, et al. (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30: 531-536.
14. Randall RE, Young DF, Southern JA (1988) Immunization with solid matrix-antibody-antigen complexes containing surface or internal virus structural proteins protects mice from infection with the paramyxovirus, simian virus 5. J Gen Virol 69: 2517-2526.
15. Michalak T (1978) Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol 90: 619-632.
16. Brown SE, Howard CR, Zuckerman AJ, Steward MW (1984) Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides.. Lancet 2: 184-187.
17. Zheng BJ, Ng MH, He LF, Yao X, Chan KW, et al. (2001) Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 19: 4219-4225.
18. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, et al. (2004) Selective functional deficit in dendritic cell T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 11: 217-224.
19. Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, et al. (2007) Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25: 1771-1779.
20. Aloman C, Wands JR (2003) Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology 38: 1584-1587.
21. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, et al. (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180.
22. Cohen J (1994) Vaccines get a new twist. Science 264: 503-505.
23. Pol S, Michel ML (2006) Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 5: 707-716.
24. Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121-130.
25. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, et al. (2001) Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34: 139-145.
26. Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD (2004) A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 3: 188-193.
27. Schuurhuis DH, van-Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, et al. (2006) Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176: 4573-4580.
28. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van-Schip JJ, Sedlik C, et al. (2002) Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTI, responses in vivo. J Immunol 168: 2240-2246.
29. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC 2004 Promotion of B cell immune responses an reduced myeloid cell population. Science 304: 1808-1810.
30. Brewer JM (2006) (How) do aluminium adjuvants work. Immunol Lett 102: 10-15.